Skip to main content
Top
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Erratum

Erratum to: Reduced expression of AMPK-ß1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer

Authors: Cuilan Li, Vincent WS Liu, Pui Man Chiu, Kwok-Ming Yao, Hextan YS Ngan, David W Chan

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Excerpt

After publication of this article [1] the authors noticed an error in Figure 5A, B and D (Figure 1 here). In Figure 5A (Figure 1 here), the same image from AMPK-β1 was erroneously used for pAMPKα of A2780cp- β1 panel. The correct image for pAMPKα is now provided. In Figure 5B and D (Figure 1 here), the panel of OV2008-sh β1 used two different sets of b-actin. The b-actin in Figure 5B (Figure 1 here) is now used for the whole panel of OV2008-sh β1 in Figure 5B and D (Figure 1 here). These errors were unintentionally made during figure preparation and do not in any way alter the results or conclusions of this study. The authors apologize that these errors were not detected earlier.
Appendix
Available only for authorised users
Literature
1.
go back to reference Li C, Liu VWS, Chiu PM, Yao KM, Ngam HYS, Chan DW: Reduced expression of AMPK-ß1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer. Mol Cancer. 2014, 13: 49-PubMedCentralCrossRefPubMed Li C, Liu VWS, Chiu PM, Yao KM, Ngam HYS, Chan DW: Reduced expression of AMPK-ß1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer. Mol Cancer. 2014, 13: 49-PubMedCentralCrossRefPubMed
Metadata
Title
Erratum to: Reduced expression of AMPK-ß1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer
Authors
Cuilan Li
Vincent WS Liu
Pui Man Chiu
Kwok-Ming Yao
Hextan YS Ngan
David W Chan
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-161

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine